Lexaria Bioscience provides update on DehydraTECH technology

Lexaria Bioscience (LEXX) provides the following glucagon-like peptide-1strategic update as the industry continues to outperform earlier revenue growth projections. Despite remarkable revenue growth there is a significant problem still plaguing the GLP-1 industry: unwanted adverse effects led by gastrointestinal issues, namely nausea, vomiting, diarrhea and constipation. Lexaria’s patented DehydraTECH technology offers a solution. By enhancing the performance of oral dosing choices as a replacement for disliked injections, and by reducing AEs and especially gastrointestinal AEs, Lexaria’s proprietary DehydraTECH technology could be of vital importance to the GLP-1 sector in the pursuit of better tolerated GLP-1 drugs. As Lexaria has previously reported on August 28, 2024, January 14, and June 11, DehydraTECH-GLP-1 processing has repeatedly shown in human clinical testing its propensity to reduce side effects, including but not limited to gastrointestinal AEs, in all 3 of the top GLP-1 drugs currently available in the world today, being Eli Lilly and Company’s drug tirzepatide, and Novo’s drugs semaglutide and liraglutide. Lexaria is executing its multi-faceted strategy centered around its proprietary DehydraTECH processing technology. Our main goal is to attract pharmaceutical companies seeking the benefits of adopting Lexaria’s DehydraTECH technology for use with their own existing drug products. This first prong of the strategy has been evidenced and validated by the Company’s entry in a material transfer agreement with a pharmaceutical company which was announced in September of 2024. Lexaria continues to collaborate with PharmaCO on evaluating DehydraTECH compositions and potential next steps.